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Abstract
Background: Autosomal dominant (AD) diseases result when a single mutant or non-functioning gene is present on 
an autosomal chromosome. These diseases often do not emerge at birth. There are presently two prevailing theories 
explaining the expression of AD diseases. One explanation originates from the Knudson two-hit theory of hereditary 
cancers, where loss of heterozygosity or occurrence of somatic mutations impairs the function of the wild-type copy. 
While these somatic second hits may be sufficient for stable disease states, it is often difficult to determine if their 
occurrence necessarily marks the initiation of disease progression. A more direct consequence of a heterozygous 
genetic background is haploinsufficiency, referring to a lack of sufficient gene function due to reduced wild-type gene 
copy number; however, haploinsufficiency can involve a variety of additional mechanisms, such as noise in gene 
expression or protein levels, injury and second hit mutations in other genes. In this study, we explore the possible 
contribution to the onset of autosomal dominant diseases from intrinsic factors, such as those determined by the 
structure of the molecular networks governing normal cellular physiology.
Results: First, simple models of single gene insufficiency using the positive feedback loops that may be derived from a 
three-component network were studied by computer simulation using Bionet software. The network structure is 
shown to affect the dynamics considerably; some networks are relatively stable even when large stochastic variations 
in are present, while others exhibit switch-like dynamics. In the latter cases, once the network switches over to the 
disease state it remains in that state permanently. Model pathways for two autosomal dominant diseases, AD 
polycystic kidney disease and mature onset diabetes of youth (MODY) were simulated and the results are compared to 
known disease characteristics.
Conclusions: By identifying the intrinsic mechanisms involved in the onset of AD diseases, it may be possible to better 
assess risk factors as well as lead to potential new drug targets. To illustrate the applicability of this study of pathway 
dynamics, we simulated the primary pathways involved in two autosomal dominant diseases, Polycystic Kidney 
Disease (PKD) and mature onset diabetes of youth (MODY). Simulations demonstrate that some of the primary disease 
characteristics are consistent with the positive feedback - stochastic variation theory presented here. This has 
implications for new drug targets to control these diseases by blocking the positive feedback loop in the relevant 
pathways.
Background
Many human genetic diseases result from loss-of-func-
tion germline mutations in one of the two homologous
gene loci. These are often referred to as autosomal domi-
nant diseases because of frequent phenotypic dominance
of the mutated allele over the wild-type allele during
transmission along generations. There are presently two
prevailing theories explaining the autosomal dominant
expression of these diseases. One explanation originates
from the Knudson two-hit theory of hereditary cancers,
w h e r e  l o s s  o f  h e t e r o z y g o s i t y  o r  o c c u r r e n c e  o f  s o m a t i c
mutations impairs the function of the wild-type copy [1-
3]. While these somatic second hits may be sufficient for
stable disease states, it is often difficult to determine if
their occurrence necessarily marks the initiation of dis-
ease progression [4,5]. A more direct consequence of a
heterozygous genetic background is haploinsufficiency,
r e f e r r i n g  t o  a  l a c k  o f  s u f f i c i e n t  g e n e  f u n c t i o n  d u e  t o
reduced wild-type gene copy number; however, haploin-
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sufficiency can involve a variety of additional mecha-
nisms, such as noise in gene expression or protein levels,
injury and second hit mutations in other genes [6]. These
stochastic factors are likely to contribute to the character-
istics of variable time of onset and incomplete penetrance
of many autosomal dominant diseases [7]. In this study,
we explore the possible contribution to the onset of these
diseases from intrinsic factors, such as those determined
by the structure of the molecular networks governing
normal cellular physiology.
Cook (1998) proposed that stochastic gene expression
might play a role in haploinsufficiency disease. The pri-
mary mechanism suggested was the stochastic fluctua-
tion of gene expression that could cause an essential gene
product to fall below some critical level. Since then a
number of papers have supported this theory by quanti-
fying variability in gene expression [8-13]. One potential
weakness of this theory is that the disease condition
should be expected to improve or disappear when the
gene product levels return to normal or the mean level
[14]. In order to achieve a stable disease state, an addi-
tional switching mechanism may be involved. A common
switching mechanism found in biological systems is a
positive feedback loop structure.
Positive feedback loops are network structures that
appear to have two functions in biological systems: they
act as rapid switches to turn on a process [15,16] and they
act as noise buffers to enable a system to respond to long
term signal changes while resisting the effects of transient
fluctuations [16]. Because of this dual ability, it was sug-
gested that positive feedback loops impart an evolution-
ary advantage as a biological switch mechanism.
However, positive feedback loops that balance both these
properties are difficult to achieve because such positive
feedback systems may depend on having production rates
of key components that are high enough to overcome the
effects of noise or environmental perturbations and yet
low enough to maintain sensitivity. When one allele of a
critical gene is lost, as in the case of autosomal dominant
disease background, the stability of the noise-resistant,
rapid-on switch may be compromised.
Experiments with small networks of neurons as well as
simulations have shown that networks composed of both
excitatory and inhibitory elements can exhibit complex
behavior [17,18]. One of the principle characteristics of a
complex system is sensitive dependence on initial condi-
tions [19,20]. Small perturbations to the system may
cause large changes in the system, including rapid
changes to new states; in other cases, large perturbations
may cause little change to the system. A network com-
posed of positive feedback loops and a combination of
activation and inhibition may exhibit complex system
characteristics.
Two important sources of noise in biological networks
are gene expression fluctuations on several time scales
and environmental perturbations due to such events as
injury or disease. Variability in protein levels occurs on a
range of time scales, from minutes to many cell lifetimes
to permanent (Sigal, et al., 2006). On the most rapid scale,
protein levels were found to fluctuate on time scales of 15
to 50 hours or 0.8 to about 2.5 cell cycles. Fluctuations
were highly correlated between proteins in the same
pathway, but not between different pathways, implying
that most of the variability is due to upstream regulatory
components in specific pathways. Stochastic gene expres-
sion noise has been explained by several different mecha-
nisms [21,22]. When two alleles are functioning properly,
random fluctuations in gene expression may play a posi-
tive role in cellular networks and are thought to be
important for cell differentiation and autostabilization
[23,24]. Stochastic gene expression might also provide a
simple mechanism for organisms to explore genetic
design space without having to go through the all-or-
none drastic step of gene mutation. Environmental noise
caused by injury or disease is more difficult to character-
ize than the noise in gene expression, in part because it
can result from many different causes. Nevertheless, per-
turbations external to cells can have a marked temporary
effect on cellular networks that can be prolonged by cer-
tain network structures.
In this paper, we explore the hypothesis that the combi-
nation of network noise together with positive feedback
loops results in dynamic behavior that can explain the eti-
ology of some autosomal dominant diseases. A number of
positive feedback network structures are examined using
modeling to simulate the dynamics when the expression
level of key components is reduced by one half and sub-
jected to Gaussian noise to simulate stochastic gene
expression. Key factors that affect network response are
the time scale of random fluctuations, amplitude of the
variation, and the structure of the feedback loop.
All network simulations were done using Bionet soft-
ware, which is available through the Stanford Simbios
National Center for Biomedical Computing website [25].
The fuzzy logic methodology in Bionet is common in the
design and modelling of advanced control systems in
many engineering disciplines. This approach was
adopted for pathway modeling to allow experimental
biologists to use the kind of qualitative data found in typ-
ical journal articles to describe the interaction of genes,
proteins, and other cellular components to create com-
puter models of large numbers of interacting compo-
nents. Fuzzy network modeling can be used as a tool for
aiding human reasoning when many interacting variables
participate in complex interaction networks on several
scales. Though the interactions can sometimes only beBosl and Li BMC Systems Biology 2010, 4:93
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described approximately, the logic of the interactions is
rigorous. Importantly, Bionet simulates network dynam-
i c s  a s  a c c u r a t e l y  a s  d i f f e r e n t i a l  e q u a t i o n  m o d e l s ,  b u t
without explicitly defining equations. Detailed informa-
tion about the modeling methodology in Bionet can be
found in [26].
The goal of this study is to examine the effect of haplo-
insufficiency on network dynamics and to illustrate that
the combination of stochastic gene expression and cer-
tain network structures may explain some autosomal
dominant disease characteristics. Parameters that repre-
sent gene expression levels in the following simulations
must be set so that when 2 genes are functional, the net-
work is stable. But if the expression levels are set too high,
then disabling one gene will never have any effect. The
expression level of one gene should be set so that the net-
work is still stable if there is no noise in the expression.
Otherwise, since the network dynamics is deterministic
when no noise is present, the network will always fall into
one final state immediately. The characteristic of auto-
somal dominant diseases that is to be simulated here is
onset that does not occur immediately, but exhibits some
variation in the age of onset. This can only be achieved
when the expression parameters are in a relatively narrow
range. Furthermore, only one gene is heterozygous at a
time. The normal, homozygous genes both express at
normal levels and thus variations in their levels will not
degrade the network performance. These simulation con-
ditions reflect the hypothesis to be tested here: haploin-
sufficiency of a single gene in the key pathway for an
autosomal dominant disease may affect the disease state
for certain network structures.
Results
Three component positive feedback loop simulations
All of the possible positive feedback loops that may be
derived from a three-component network are shown in
Figure 1. A positive feedback loop is defined here as a
loop that encompasses at least two nodes and has an even
number of negative regulators, either zero or two, in the
loop. In each case, X is the signalling protein at the top of
the loop, Y an intermediate protein, and D is a marker for
the disease state. Simulations were run with either X or Y
production reduced by one half, as a consequence of
heterozygosity, and Gaussian noised added to the expres-
sion of the affected gene product. Time steps of one half
week, and thus random variation on the same time scale,
were similar to the lower end of random variations
reported earlier [21]. Figure 2 shows time courses over an
80-year period for all of the loops in the X-heterozygosity
case and Figure 3 shows the Y-heterozygosity cases. This
time span was chosen to approximately represent a nor-
mal human lifespan. Network structures that cause D to
increase to high levels early and irreversibly may be char-
acterized as allowing or causing a high level of disease
symptoms. These include 2.a, 2.c and 3.b for X-heterozy-
gosity and all of the type 3 loops for Y-heterozygosity.
Milder or variable disease symptoms may be expected
when the D time course is somewhat repressed or arises
intermittently. These include 1.c and 2.b for X- heterozy-
gosity and 1.a, 1.c, all type 2 loops for Y heterozygosity.
No disease occurs in networks 1.a, 1.b, 3.a and 3.c for X-
heterozygosity; no such cases occur for Y-heterozygosity,
although 1.b has a very low level of variable disease pres-
ence. These results are summarized in Table 1. The char-
acterization of network dynamics in terms of disease
onset as mild is somewhat general, with a wide range of
dynamic responses possible. The severe labels (++) indi-
cate cases where disease onset would be expected to be
early, symptoms relatively stable and the likelihood of
occurrence almost certain.
Sensitivity to Noise
Sensitivity of the networks examined above to parameter
changes is a key issue. The critical parameter in this study
is the amount of variation in the haploinsufficient gene,
which is equivalent to the production rate of the relevant
protein. Note that 'production rate' in our models is syn-
onymous with 'expression level'. In all of the networks,
Figure 1 Positive feedback loops. All possible configurations of pos-
itive feedback loops that can be derived from a three component net-
work.Bosl and Li BMC Systems Biology 2010, 4:93
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including those for specific diseases discussed below, the
behavior of the network is completely determined and
stable when expression levels are constant. Furthermore,
in order to simulate the biological conditions of interest,
the expression level of the network elements is such that
when two genes are functioning, the network is uncondi-
tionally stable. That is, the production rate is high enough
that the network remains in the disease-free state even in
the presence of noise or variation in rate. If a single gene
mutation occurs so that only one gene is operative, the
pr oduction ra t e of t ha t gene cannot be so high t ha t it
effectively eliminates the haploinsufficiency condition. If
the expression levels are set so high or low that the ran-
dom variation is irrelevant, then, again, the final steady
state of the system will be completely determined from
the start: the disease will either be present always or
never. Therefore, the parameters that control expression
levels in this study are necessarily set near critical points
for single genes. The assumption underlying this entire
study is that two genes must express sufficiently for a sta-
ble, non-disease state to exist even when the expression
levels vary stochastically, while a single gene is such that
the disease state sometimes occurs, sometimes does not.
This is the characteristic of autosomal dominant disease
that the simulations seek to reproduce and explain.
The critical parameter that is relevant to autosomal
dominant disease in the simulations presented here is the
magnitude of the concentration variation of the relevant
protein. The protein concentration varies because of ran-
dom expression variation of the deficient geneThat is, the
rate of production varies, but the concentration of the
product is what is relevant to the disease state. Some of
the network types exhibit a linear and reversible depen-
dence of the disease state on the magnitude of stochastic
variation in the haploinsufficient gene. In Figure 2, 1c and
2b exhibit this behavior and in Figure 3 all of types 1 and
2 exhibit this behavior. Even if the relevant deficient gene
expression level temporarily drops to zero, the disease
state, represented by D, decreases again when gene
expression rises.
The variation in protein concentration due to adding a
Gaussian noise term to the production rate is illustrated
Figure 2 X haploinsufficiency. Simulation results for each of the networks in Figure 1 when X is haploinsufficient and Gaussian noise is added to X 
production.
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in Figure 4. The curves are offset for visual illustration.
Each curve represents a protein concentration that is
maintained by a constant decay rate and a production
rate that consists of a constant plus a Gaussian random
noise term. The noise in each of these cases has a stan-
dard deviation of either 1.0 or 0.2. Since the concentra-
tion is affected by how long the production rate term
deviates from its average value, the time step over which
the random variation is changing also affects the concen-
tration variability. It is clear in Figure 4 that a longer time
for production rate deviation results in larger variability
in product concentration.
When the disease state is involved in the feedback loop
as in Figure 2a, a natural instability exists. The two stable
Figure 3 Y haploinsufficiency. Simulation results for each of the networks in Figure 1 when Y is haploinsufficient and Gaussian noise is added to X 
production.
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Table 1: Noise and haploinsufficiency in different loop structures
Network Type Network Type a b c
1X  d e f i c i e n t
Y deficient
0
+
0
-
+
+
2X  d e f i c i e n t
Y deficient
++
+
-
+
++
+
3X  d e f i c i e n t
Y deficient
0
++
++
++
0
++
Effect of Gaussian noise and haploinsufficiency on disease dynamics with different positive feedback loop structures. ++ indicates early, 
irreversible and severe disease onset; + indicates disease onset is variable and slightly suppressed; - are cases where disease fluctuates 
randomly, but reversibly and is suppressed as soon as the appropriate protein rises or falls; 0 indicates no disease occurs.Bosl and Li BMC Systems Biology 2010, 4:93
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states of interest are the presence or absence of disease. In
all cases the initial state is assumed to be the absence of
disease; D is initially zero. This prevents the situation
where D is initially high and is involved in a feedback loop
that completely blocks a switch to a low D state and is
biologically realistic because haploinsufficiency diseases
do not often exhibit the disease state immediately and
deterministically. In network type 2.a, if X is initially set
above a critical level, Xc0, and there is no stochastic vari-
ability, D will remain near zero, as shown in Figure 5a.
Similarly, if X is set below Xc0, D will rise to its highest
level and remain there. A plot of the latter case will be
very similar to Figure 5b.
The response of network 2a to variations in stochastic-
ity when X is deficient is an example of a network with
two stable states, disease-free and disease. In order to
study network behavior with different levels of the noise
parameter, 100-simulation trials were run and the final
state of the system was determined. Single snapshots of
the 100-simulation trials are shown in Figure 5 and the
statistical results in Table . a2. a. When no noise is present
in X, the system dynamics are deterministic. Expression
levels are defined and set as follows. The critical expres-
sion level for the gene X is determined empirically
through computational experimentation. This is the basal
expression level for a single gene in this sensitivity study.
Define the normal expression level to be when two genes
each express at the critical level. This will be considered
100% expression or normal expression. Haploinsuffi-
ciency occurs when one gene is inactive and the expres-
sion level is expected to be 50% of normal. In Figure 5,
50% refers to a single gene expressing or producing pro-
tein X at a rate that prevents D from rising in the deter-
ministic case (no noise in the expression level). If the
expression level is lowered by a small amount, for exam-
ple 49%, D will rise. Note that the graphs in Figure 5 show
protein levels, but the stochastic variation is in the rate of
protein production. The expression levels, such as 50%,
refer to the production rate of the protein, not the actual
concentration that is plotted. The basal rate is constant
Figure 4 Effect of Gaussian noise added to production rate on product concentration. Gaussian noise added to the production rate causes 
changes in the concentration of the protein. The standard deviation of the noise, σ, and the size of the time step over which the rate is changing, Δ, 
both affect the size of the concentration variations as shown here.Bosl and Li BMC Systems Biology 2010, 4:93
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throughout the simulation, with Gaussian noise added to
the rate.
The stochastic variation in all simulations in this study
is determined by adding a zero-mean Gaussian value to
the basal expression rate. The standard deviation of the
Gaussian term is denoted by σ. Thus, (0, 0.5) noise refers
to a Gaussian distribution centered on zero with a stan-
dard deviation of 0.5. In the simulations, a single value is
chosen from this distribution at each time step and added
to the basal production rate. Since the random variable
can be either positive or negative (since the mean of the
random variables is zero), the expression rate at any time
step is above or below the basal value. When time steps
are longer, the relative time that the rate is above or below
Figure 5 Illustration of network response to changes in stochastic parameters. The response of network 2a to variations in stochasticity when 
X is deficient is used here to illustrate the effect of changing the noise added to production rate on the product concentration. These are single snap-
shots of the 100-simulation trials shown in table 2. Note that the normalized protein concentration is plotted, while the expression level refers to the 
rate of protein production; the rate is not plotted.Bosl and Li BMC Systems Biology 2010, 4:93
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the basal value is longer and the actual protein concentra-
tion drifts farther from its equilibrium value. Thus larger
time steps with the same random distribution cause
greater variation in the protein concentration.
As can be seen in Figure 5a, the network is stable with
one gene when there is no noise. The remaining cases in
Figure 5 illustrate the effect of both raising the basal level
of expression of the single functioning gene and changing
stochastic variation. For the random variation, two
parameters are varied. Gaussian noise is added to the
expression rate, not the actual value of the protein con-
centration. The time parameter shown is the length of
time over which the expression rate varies. If the time
variation is small, the actual protein concentration varies
little. As the time for stochastic variation increases, there
is greater chance of the key protein, X, drifting via a ran-
dom walk far enough from the critical value to cause the
disease state to increase. Positive feedback then enables a
switch to the full disease state. As the basal expression
level increases, the penetrance of the disease state
decreases. At 60% of normal expression (Figure 5f), the
largest noise level used in this study does not allow dis-
ease to grow in any trials.
Summarizing the results described above, for a model
of autosomal dominant disease based on stochastic varia-
tion and positive feedback network structures, several
key parameter values are required. First, the expression
level of a single gene has to be near a critical point. If the
expression level of a single gene is too high or low, the
disease will either never be present or always be present
from birth. Second, the stochastic variation in expression
level must have a large enough deviation from the mean
to cause the concentration of the key protein concentra-
tion to dip low enough to trigger positive feedback from
the disease state. But this alone is insufficient; the length
of time of the variations in expression rate must be long
enough to affect the concentration of the protein. Con-
centrations do not respond immediately to a drop in
expression, but depend on the rate of protein decay.
The following disease models are not intended to deter-
mine the precise stochastic parameters that are operative
in each of the pathways presented, rather to illustrate
with reasonable parameters that the presented disease
mechanism is plausible and should be investigated fur-
ther.
Polycystic Kidney Disease
Autosomal Dominant Polycystic Kidney Disease
(ADPKD) is a common hereditary disorder characterized
by cystic dilation of the kidney tubules, eventually leading
to enlarged cysts isolated from their nephrons [27]. The
resultant decrease in kidney function often necessitates
hemodialysis or organ transplantation. The majority of
ADPKD (85-90%) are caused by mutations within PKD1,
encoding a 460 kDa G protein-coupled receptor known
as polycystin-1 (PC1) [28,29]. Mutations in a second
Table 2: Sensitivity of feedback loop to changes in stochasticity parameters
Trial Expression level Noise stdev Time scale (days) Penetrance Mean onset
1b 50% 0.2 2 0.31 2.1/5.9
2 50% 0.5 2 0.94 22.1/20.4
3 50% 1.0 2 1.0 12.5/10.6
4 50% 0.2 5 0.91 21.9/21.8
5c 52.5% 0.5 2 0.20 6.1/18.7
6 52.5% 1.0 2 0.95 17.8/15.9
7d 52.5% 0.5 5 0.54 7.5/13.0
8 52.5% 1.0 5 1.0 22.0/18.5
9 55% 0.5 2 0.0 --
10 55% 0.5 5 0.0 --
11e 55% 1.0 2 0.34 8.8/19.2
12 55% 1.0 5 1.0 2.7/0.1
13f 60% 1.0 5 0.0 --
Sensitivity of feedback loop 2.a to changes in stochasticity is illustrated here using 100-trial simulations. Expression level is such that 50% is 
at the critical level: slightly lower expression, with no noise, allows disease to deterministically occur all the time. 100 simulations for each set 
of conditions were run to compute a penetrance value. When no noise is present, the system is deterministic and no disease occurs as long 
as the base expression level is 50% or higher. When expression is 60% or higher, no disease occurs even with the highest level of random 
variation used in this study.Bosl and Li BMC Systems Biology 2010, 4:93
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gene, PKD2, abrogate the function of the Ca2+-permeable
cation channel protein, polycystin-2 (PC2) and account
for 10-15% of ADPKD [30-33].
The autosomal dominance of ADPKD refers to the fact
that patients carrying a heterozygous mutation in one of
the PKD genes have a high chance of disease in their life-
time. However, there is no evidence that the proteins
encoded by the mutant alleles acts dominantly over the
wild-type allele product. In mouse, heterozygous inacti-
vation of one of the PKD genes also leads to development
of kidney cysts in 20-40% of the animals [34]. The main
hypothesis in the field currently proposes that disease
onset in ADPKD is triggered by somatic "second hit"
mutations that inactivate the functional copy of the PKD
gene followed by colonal expansion of the affected cells
[35]. However, other studies indicate that polycystins are
expressed in most cyst lining cells, and even "wild-type"
cells can contribute, to a large extent, to cyst growth in
the presence of PKD1 mutant cells in chimeric mice, sug-
gesting that somatic mutations may not be the only
mechanism to induced ADPKD [36-40].
Alternative to genetic changes, it is possible that some
environmental or non-genetic factors, probably those
embedded in the cellular networks involving polycystins,
promote the dominant phenotypic expression of ADPKD.
In a recent study [41], it was shown that the inflammatory
cytokine, TNF-α, negatively modulates the function of
PC2 and promotes cyst formation in Pkd2+/- mice. PC2,
in turn, negatively regulates the level of TNF-α convert-
ing enzyme (TACE) and TNF-α receptor. An increase in
TNF-α in renal tissues can also be caused by injury or
infection or by cystic conditions as the cytokine was
found to accumulate in cyst fluid from human ADPKD
patients. These interactions form a network that con-
nects cytokine, polycystin and cystic disease through two
feedback loops belonging to loop types 3a and 3c (Figure
6a). Both of these feedback loops could potentially induce
a stable disease state if a polycystin (positioned as Y in the
feedback loops) is affected by heterozygosity.
Computer simulation with the Bionet program [26]
were developed to test the potential role of the above net-
work in the onset of cystogensis associated with ADPKD.
PC1 and PC2 are modeled as a functional unit, the level
of which is affected by gene dosage of PKD1 and PKD2,
as well as proper targeting of PC2 to the cilia, which is
inhibited by TNF-α (through induction of a protein called
FIP2). There are two sources of random fluctuations in
the model: stochastic gene expression and renal injury.
The latter occurs infrequently but is sufficient to generate
transient spikes in TNF-α production. In the wild-type
population, the fluctuation in functional PC1-PC2 level is
less in magnitude than in the heterozygous background
and is always above the functional threshold required for
preventing cyst initiation (Figure 6b). However, in the
heterozygous background, where the level of expression
is in general sufficient to suppress cyst formation, ran-
dom fluctuations may cause the feedback loops to be
switched on and cyst growth continues unabated (Figure
6c, a random simulation example is shown). This result
suggest that a simple network structure could mimic the
effect of somatic mutations in disease induction, but the
difference is that in the former case, if the TNF-α feed-
back loop is disabled, full-scale cystogenesis can be pre-
vented even with stochastic sub-threshold dips in the
polycystin level (Figure 6d). Indeed, in a mouse ADPKD
model, blocking TNF-α signaling inhibited cyst forma-
tion [41].
Maturity onset diabetes of the young
Maturity onset diabetes of the young (MODY) is a clini-
cally heterogeneous group of disorders characterized by
an autosomal -dominant mode of inheritance [42]. The
diagnosis of MODY can be differentiated from type 2 dia-
betes in young patients by family history and the presence
(or a lack) of obesity. Patients may have mild hyperglyce-
mia, while others have varying degrees of glucose intoler-
ance before developing persistent hyperglycemia. Onset
is usually before age 25 and often in childhood or adoles-
cence [42]. In some cases the onset of symptoms may be
rapid. Symptoms may be mild to more severe, but in all
forms of MODY the problem is insulin deficiency due to
a defect in pancreatic b-cell function rather than a defect
in insulin action [43]. Mild hyperglycemia may be present
for years before symptoms become recognizable and a
diagnosis is made, typically between 10 and 30 years of
age. In some cases, progression from asymptomatic to
hypoglycemia requiring oral medication or insulin may
happen quickly [43]. Unfortunately, even mild but
untreated elevated blood sugars may cause injury to
organs over many years, causing such conditions as neu-
ropathy, retinopathy, renal disease, heart disease and the
other detrimental complications of diabetes.
The primary types of MODY, the responsible gene defi-
ciencies and typical treatment (indicative of severity) are
shown in Table 3. One of the genes encodes the glycolytic
enzyme glucokinase (associated with MODY2) and the
others encode transcription factors. MODY types 1 and 3
are caused by mutations to the hepatocyte nuclear fac-
tors, hnf-4a and hnf-1a respectively [43,44]. Though
MODY3 is more common than MODY1, the mechanism
of action and phenotypes are similar. With both of these
types, patients may respond to oral drugs early in the dis-
ease course, but over time fail to respond to these drugs
and symptoms worsen [42-44]. MODY2 is caused by loss
of a single allele of the glycokinase gene and tends to have
milder symptoms that can often be controlled by diet and
exercise alone. MODY types 4 and 5 are rare; MODY4
usually has mild symptoms [45], while MODY5 tends toBosl and Li BMC Systems Biology 2010, 4:93
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have more severe symptoms, requiring treatment with
oral hypoglycemic agents or insulin [44].
The key pathway involved in MODY onset is shown in
Figure 7. This pathway contains a network structure of
type 1c, but the dynamics are complicated by another
embedded sub-network of type 1c and extra feedback
loops. As seen in Figure 2, networks of type 1c are more
sensitive to deficiencies in X than in Y (Figure 3). The
implication is that an upstream component will have a
more significant impact on the network dynamics when a
deficiency in production exists.
To gain some understanding of the effect of the feed-
back loops on system dynamics, simulations of the
MODY network were carried out with the Bionet model-
ing program [26]. To generate results for statistical analy-
sis, 100 80-year simulations were run for each of the
MODY type 1 through 5. The plots in Figure 7 show typi-
cal results from one 80 year simulation for of each of
MODY types 1 through 5. Simulations are intended to
demonstrate the role of network structure, particularly
the feedback loops, on network dynamics. The time
scales and relative reaction rates were set to give realistic
output values, but are not intended to reproduce precise
second-by-second enzyme kinetics (for model details, see
Methods). Insulin production level in the model was used
as a marker for disease severity. Overall, deficiencies in
gene production higher up the cascade might be expected
Figure 6 TNF-α-mediated feedback loops in the control of ADPKD onset. a. Pathway diagram of the proteins and network involved in cytogen-
esis. b. Simulation of time courses of primary network components in the wild-type case. Random (Gaussian) noise is added to the expression level of 
each polycystin allele. Random fluctuations are damped because the expression noise in the two genes is uncorrelated. c. Heterogeneous background 
simulation. The level of polycystin is lower and the fluctuations are higher. d. Heterogenous background simulation, but with the TNF-α feedback loop 
disabled. Random fluctuations allow cyst formation to occur, but these are suppressed as soon as above-threshold expression of TNF-a is restored.Bosl and Li BMC Systems Biology 2010, 4:93
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to cause more severe downstream effects on insulin pro-
duction.
Although the model for this pathway is deterministic,
the imposition of stochastic fluctuations on the expres-
sion level of the involved genes causes every simulation
time series to be different and potentially to have a differ-
ent outcome. As discussed previously, if the system has
complex or nonlinear characteristics, small perturbations
can result in large outcome changes. The random varia-
tion in each allele is independent of the other. When two
alleles are present the total protein production rate is rel-
atively high and random variation of each allele offsets
the other. When a gene is haploinsufficient, random fluc-
tuations are higher, sometimes sufficient to engage the
positive feedback loop, resulting in disease onset. The
mean age of disease onset, variability in age of onset and
the mean insulin level (indicative of disease severity) were
computed for each set of simulations. Known disease
characteristics and simulation results are shown in Table
3.
The sample simulations in Figure 8 are representative
of the behavior for that MODY type, though the age of
disease onset may vary considerably depending on the
type. MODY2, for example, exhibited relatively uniform
dynamics for all simulations, with consistent early onset
but mild hypoglycemia (indicated by moderately low
insulin level). MODY4 simulations show the most varia-
tion in age of onset, which is not apparent in a single plot,
but insulin levels were relatively uniform after disease
onset. The MODY4 network appears to have two stable
states, either no disease at all or very high disease level
(low insulin production) and the transition from no dis-
ease to disease state occurs rapidly at a wide variety of
ages. This is typical of complex system behavior, although
we have not done the requisite mathematical analysis to
establish true complex system characteristics [19].
In simulations, MODY2 (glycokinase insufficiency)
appears to be milder than the other types and does not
worsen with time, perhaps because glycokinase is not
involved in any feedback loop. Onset of MODY2 in our
models is consistently early, under age 10, which is con-
sistent with known characteristics of MODY2 [42,44].
Once the disease is present, insulin deficiency in our
model is relatively mild, also consistent with observed
disease characteristics.
Insulin production in MODY types 1 and 3 is signifi-
cantly reduced in simulations, but fluctuates without fall-
ing to zero even after disease onset. When either of the
deficient gene products increases due to random fluctua-
tions, insulin production increases slightly. The mean
insulin level after disease onset in our models for
MODY1 and MODY3 is significantly lower than for
Table 3: MODY characteristics
MODY type Gene deficiency Prevalence(1) Treatment(1,2) Simulated mean/std 
of onset age
Simulated mean/std 
insulin
1 Hnf-4α Uncommon Oral medication or insulin 10.3/1.2 0.18/0.02
2 glycokinase Common Diet and exercise 4.5/0.3 0.26/0.005
3 Hnf-1α Most common Oral medication or insulin 24.0/8.1 0.24/0.08
4 Pdx1 Rare Oral medication or insulin 22.6/11.0 0.22/0.11
5 Hnf-1β Rare Insulin 9.3/0.4 0.08/0.004
Observed and simulated characteristics of the five major MODY types. The absolute magnitude of the simulated values is not as important as the 
relative values. The standard deviation in the age of onset is much larger for MODY3 and MODY4, which should be reflected in a range of onset 
ages in epidemiological data. Mean and standard deviation of the insulin levels is related to the severity of the disease. Data for "Prevalence" from 
[42,44].
Figure 7 Key pathway involved in MODY diabetes. The pathway 
components highlighted in red illustrate that the basic network struc-
ture is of type 1.c, with a subnet of type 1.c embedded in a larger net-
work of the same type. The disease type that results from 
haploinsufficiency of each gene is shown in parentheses.
	

	



	


	






	



	 	






	




	 











 !!	 Bosl and Li BMC Systems Biology 2010, 4:93
http://www.biomedcentral.com/1752-0509/4/93
Page 12 of 15
Figure 8 MODY simulations. Simulations of the MODY pathway shown in Figure 7 are shown for haploinsufficiency of hnf1a, glycokinase, hnf4a, Pd 
× 1 and hnf-1brespectively corresponding to MODY types 1 through 5.
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MODY2. Clinically, MODY 1 and MODY 3 have similar
presentations. The differences in our simulations are pri-
marily due to placement in the loop structure, although it
is somewhat complicated by the double feedback from
hnf4a to upstream components, hnf1a and pdx1. MODY
1 is quite rare, with only 13 families identified worldwide
as of 2001 [42]. Our simulations suggest that the primary
difference between these two forms is the age of onset
and variability in the age of onset. The age of onset for
MODY1 is earlier and less variable, starting at about 10
years, while MODY3 starts much later (average age 24 in
our simulations) and the age of onset is much more vari-
able. The mean insulin level after disease onset is higher
in MODY1, suggesting possibly milder symptoms. It is
important to emphasize that the ages and levels in our
simulations should be interpreted in a relative sense to
gain an understanding of how pathway dynamics might
affect disease characteristics. The values and ages should
not be considered precise predictions.
Deficiencies in pdx1 (MODY type 4) and hnf1bMODY
type 5 might be expected to have the most severe effect
on insulin production due to the direct feedback by insu-
lin on gene expression or protein activity. MODY4 is a
form of early onset type-II diabetes mellitus associated
with a disruption in one allele of the Pdx1 or insulin pro-
moter factor-1 (IPF1) gene [45]. Age of onset tends to be
in early adulthood and symptoms are relatively mild. In
one study, ketosis and other signs of severe insulin defi-
ciency were lacking in patients with MODY4 [45]. In our
simulations, MODY4 has the greatest variability in age of
onset (11 years standard deviation) with an average age of
23 years. This is consistent with observed disease charac-
teristics. However, our MODY4 model exhibits a switch-
like behavior. Before disease onset, levels of insulin secre-
tion are steady and relatively high. This state would mani-
f e s t  a s  m i l d  o r  n o  d i s e a s e  s y m p t o m s .  W h e n  r a n d o m
variation drops insulin low enough, the feedback loop
engages and a change to the stable disease state occurs
rapidly. Once in that state, insulin production is uni-
formly low. This latter condition is not consistent with
observed symptoms, , suggesting that an additional ele-
ment in the pathway may be missing that reduces the
effect of Pdx1 deficiency. However, MODY4 is very rare,
with studies based on a single extended family [42].
When Hnf-1b is haplodeficient (MODY5), low insulin
production and disease onset appear occur consistently
early in our simulations. This is not surprising, as is
involved in a direct feedback loop between insulin secre-
tion and Pdx1 at the top of the loop. Hnf-1b results in a
distinct form of diabetes that is associated with a spec-
trum of related defects including renal cysts and internal
defects in uterus and genitalia [42]. Clearly our model
does not include interconnections with all of the other
networks that regulate development of the renal system
and other organs. Nevertheless, the key role played by
Hnf-1b in the feedback loop of Figure 7 results in early
and definitive disease onset in simulations when a haplo-
deficiency exists.
Finally, we note that [46] reported that heterozygosity
in hnf1a (+/-) on a pdx1 (+/-) background produced
strong decreases in insulin production in mice. This out-
come is not surprising in light of the above results, as a
deficiency in each of these proteins will lead to the dis-
ease state. Simulation results, shown in Figure 8, are as
expected: the double haplodeficiency causes early and
severe restriction of insulin production.
Discussion
As we have discussed elsewhere [47], network structure is
a critical determinant of network dynamics and dynamics
is often not apparent from structure without simulation.
Our purpose here was to examine simple representations
of positive feedback loop structures and their response to
noisy inputs at the top of a signaling cascade because
these mechanisms appear to be involved in many haplo-
insufficiency diseases. Our basic theory is that stochastic
gene variation in proteins that are involved in positive
feedback loops can cause network dynamics that may be
responsible for some haploinsufficiency diseases. A cata-
log of networks with feedback loops was presented and
the simulation results for each network was constructed
to illustrate the dynamics of the network structure, which
is not always evident from the visual topology of the net-
work. These simulations are intended to give insight into
the mechanisms that cause more severe disease in some
forms or mild, reversible symptoms in others.
As noted in the stochastic simulations in Figure 5, the
magnitude of expression variation and the time scale over
which it varies are both important parameters. Even
small dips in expression, if they persist long enough, may
cause significant drift of key protein concentrations from
required minimum levels and allow a disease state to
occur. If a positive feedback loop is involved, that may be
sufficient to trigger a transition to a permanent disease
condition.
Polycystic kidney disease involves a number of complex
interacting pathways that undoubtedly add to the com-
plexity of this disease. Nevertheless, the simple model
presented here seems to be able to capture some of the
essential features of this disease. In particular, the feed-
back loop involving TNF-α is a critical switch that con-
trols the change from normal function to the sustained
growth of cysts once the disease has set in. The model
results suggest that drugs that inhibit the feedback loops
are likely to be effective in reducing the disease severity.
Differences in MODY characteristics that were found
in simulations reflect many of the differences in the
actual phenotypes. The general conclusions that can beBosl and Li BMC Systems Biology 2010, 4:93
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drawn from the simulation in Figure 8 are that when net-
work components are higher up the cascade of events in a
process, the more profound their effect on system
dynamics. Several important disease characteristics
might be surmised from the simulations alone. First, hap-
lodeficiency of Pdx1 and hnf-1b are likely to cause earlier
onset and greater insulin need than haplodeficiency of
hnf4a and glycokinase. Glycokinase deficiency (MODY 2)
is likely to not worsen with age in this model because
there is no feedback loop to amplify stochastic reductions
in glycokinase. An adaptation has been observed in mice
with glucokinase related MODY (type 2). Experiments
suggest that mild hyperglycemia leads to increased
expression of the functioning glucokinase gene, thus lim-
iting the severity of the defect in glucose-stimulated insu-
lin secretion [48]. Our simulations suggest that this
increased expression is not required to explain the lim-
ited severity of MODY type 2 symptoms. The mildness of
MODY 2 rather seems to result from glycokinase not
being involved in any feedback loops in the MODY path-
way. Haploinsufficiency in the other proteins that have
feedback loops can result in definite decreases in insulin
production at specific ages when the feedback loop is
engaged. However, although insulin level decline is not as
severe even when the disease is present, the switch from
no disease to a disease state appears to be sensitive in our
simulations. The result is that disease onset tends to be
consistently early. The effect of glycokinase deficiency is
apparently felt in the loop dynamics and the switch to the
disease state requires only small stochastic perturbations
to engage.
Conclusions
In summary, results presented above show that the onset
and variability of haploinsufficient diseases may be inti-
mately linked to the structure and dynamics of the regu-
latory networks underlying the processes affected in
these diseases, which should be taken into account in
designing approaches for medical intervention. The pri-
mary purpose of the computational models is to enable
the dynamics of a complex pathway to be explored, as
dynamics are often not apparent from the appearance of
the network structure alone. While much more detailed
modeling studies are required for realistic drug target
testing, analysis of regulatory networks through simple
model simulation are useful for assessing the disease
mechanism and possibly more precise treatment options
by targeting key parts of a complex pathway.
Methods
Simulations were run with each of these networks using
the Bionet simulator [26]. The models that are derived
from the drawings in Figure 1 all have a production and
decay reaction for each of the three components. Degra-
dation is a constant first order reaction for all compo-
nents and is not regulated. Production or expression
occurs at a rate that is modulated by feedbacks as shown
in the diagram. To characterize the dynamic response of
each of the networks, simulations were run with noise
sources added to the production rates of either X or Y
separately, or to both.
Variation in gene expression was simulated with zero-
mean Gaussian noise, with standard deviation of 1.0.
Since Gaussian noise can have positive or negative values,
t h e  p r o d u c t i o n  r a t e s  w i l l  i n c r e a s e  o r  d e c r e a s e  w h e n
Gaussian noise is added. Our intention was to simulate
the effects of stochastic gene expression using Gaussian
noise. As discussed previously, gene expression can vary
significantly on time scales of hours to days. Protein con-
centrations will vary somewhat more slowly, as the pro-
tein concentration is a cumulative effect of gene
production. In our models, adding noise to the produc-
tion rate simulates this effect.
For our simulations, setting appropriate reaction rates
is essential, including production and activation or inhi-
bition effects. If production of a critical gene product is
set too high, then haploinsufficiency is irrelevant. In addi-
tion, a minimum threshold level for disease growth must
be assumed. This assumption derives naturally from the
switch-like dynamics of biological positive feedback
loops. Below a certain threshold, no reaction occurs,
while above that threshold the reaction is rapid. Other-
wise, disease growth will always be present to some
degree, except in the trivial case where all reactants have
zero concentration. As much as possible, realistic values
for rates and timescales are chosen for this study. Con-
centrations shown are normalized to the range 0 to 1. For
more detailed model input in the Bionet simulator, see
Model input files for execution in the bionet simulator,
available online at [25].
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